The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial.
Ryan McDonald
Advertisement
Articles by Ryan McDonald
Advertisement
Latest Updated Articles
KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCLPublished: May 30th 2020 | Updated:
Advertisement
Advertisement
